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Breast Cancer Specimen Collection, Handling &  
Adherence to ASCO/CAP Guidelines 
Background/Introduction 
Reports that some breast cancer specimens were not being placed in formalin consistently 
in a timely manner was identified as a quality issue within our health system, and was the 
impetus for this quality improvement project. Specimens removed from their blood supply begin 
to degrade immediately.  Specimens are placed in formalin to halt the process of degradation.  
Under-exposure of specimens to formalin can result in false positive immunohistochemical test 
results for estrogen receptors and progesterone receptors (Hammond et al., 2010) and over-
exposure of specimens to formalin can result in false negative test results for Her-2/neu receptors 
(Hicks & Schiffhauer, 2011). These test results are used to decide appropriate systemic therapy 
(chemotherapy, endocrine therapy and biologic response modifiers) for breast cancer patients 
(Harris et al., 2016).  Basing systemic treatment on inaccurate test results could result in the 
under treatment or over treatment of some patients with breast cancer, which has the potential to 
result in harm.   
In an effort to ensure the preservation of specimens and the quality of pathology test 
results, the American Society of Clinical Oncologists (ASCO), and the College of American 
Pathologists (CAP) have established guidelines for the collection and handling of breast cancer 
specimens (College of American Pathologists, 2013).  These guidelines for breast cancer 
specimen collection & handling identify critical times associated with breast cancer surgery that 
must be documented to ensure monitoring of quality results.  Two of the three critical times are 
usually recorded by surgical nurses, and one is recorded by the pathologist.  These critical times 
are used to verify that a process that was consistent with national guidelines was implemented in 
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collecting and handling the specimen and whether the specimen was under-exposed or over-
exposed to formalin.  The critical times that must be document include the exact time the 
specimen was removed from the blood supply, the time the specimen was initially placed in 
formalin, and the total time the specimen remained in formalin.  In addition to the documentation 
of these critical times, ASCO/CAP Guidelines also recommend that after initial removal from the 
blood supply, breast cancer specimens be placed in formalin as soon as possible, but not to sixty 
minutes from the time of removal.  They have also established a guideline for the total time a 
specimen remains in formalin, which is currently is a minimum of six hours and no longer than 
seventy-two hours before it is microscopically analyzed by a pathologist (College of American 
Pathologists, 2013).  The documentation of these critical times and these guidelines became the 
primary indicators for our quality improvement project, which will be discussed in detail in the 
methodology section.   
In 2014, several incidences occurred to bring problems with the collection and handling 
of breast cancer specimens to the forefront.  The incidents led to further inquiry, 
multidisciplinary team formation and a quality improvement project.  This prospectus describes 
the first three PDSA Cycles of that quality improvement project.  Initially, the leadership 
framework and theory used to underpin the project will be reviewed.  The global aim statement 
and problem statement will then be defined, followed by an overview of the project.  The project 
overview will include the goals and objectives of the project, the project plan and the specific 
aim statement.  The rationale for the project will then be discussed and will include assessments, 
analysis and other tools utilized to identify the problem and possible causes, and will end with a 
thorough cost analysis.  The methodology of the project will be delineated, followed by the 
literature review strategy and a description of selected articles and how they support the project.  
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The project timeline will then be described, and in conclusion, the expected or anticipated results 
will be reviewed followed by the author’s perspective on the significance of the project. 
Clinical Leadership Theme 
 
Leadership Framework, Magnetism Forces & Competency 
 
          The clinical leadership theory that was used for the framework of this project is 
transformational leadership.  To successfully make changes that affect a variety of disciplines in 
multiple departments of a health system, transformational leadership was chosen due to the need 
for a clear vision, effective communication, multidisciplinary team involvement and motivation 
to function at a high level of performance (Harris, Roussel & Thomas, 2014).  The CNL 
leadership competency for this project is to “effect change through advocacy for the profession, 
interdisciplinary health care team and the client by identifying clinical and cost outcomes that 
improve safety, effectiveness, timeliness, efficiency, quality and client-centered care.” 
(American Association of Colleges of Nurses, 2013).  In addition, this project is also related to 
two of the fourteen magnetism forces.  Those two forces are quality of care and quality 
improvement.  Quality of care was chosen, as it is the driving force for nursing and the magnet 
organization in an environment that benefits patient outcomes.  Quality improvement was chosen 
because the healthcare setting of this project has two magnet hospitals that both place high 
importance on quality improvement and have structures and processes in place to measure and 
improve patient care and services.  Magnet status is an award given by the American Nurses' 
Credentialing Center (ANCC), an affiliate of the American Nurses Association, to hospitals that 
participate in a survey process and also meet a set of criteria designed to measure the strength 
and quality of their nursing care and services (American Nurses Credentialing Center, 2016). 
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Global Aim Statement 
The collection and handling of breast cancer specimens will be timely and consistent with 
guidelines developed by the American Society of Clinical Oncologists, (ASCO) and the College 
of American Pathologists, (CAP) throughout the health system. 
The global aim of this project is to improve safety, timeliness, accuracy, documentation 
and compliance with ASCO/CAP Guidelines in the collection and handling of breast cancer 
specimens removed during surgery at all inpatient and outpatient surgical sites within the John 
Muir Health System in 90% of cases or above by December 31, 2016.   
The process begins with the removal of the specimen from the blood supply by the 
surgeon, documentation of the time of removal by the surgical nurse, orientation of the specimen 
by the surgeon with pins and/or stitches, handoff to a surgical nurse in the surgery department or 
outpatient surgery center, placement of the specimen in a container of formalin, labeling of the 
specimen container with the patient identifiers, documentation of the time the specimen was 
placed in formalin, completion of the form that accompanies the specimen to pathology  and 
ends with the microscopic evaluation and diagnosis by a pathologist, who ends the process by 
including the cold ischemic time and the total number of hours the specimen spent in formalin 
within the pathology report.  The quality indicators that will be measured include:  
Documentation of the time the specimen was removed from the blood supply; documentation of 
the time the specimen was initially placed in formalin; documentation of the cold ischemic time 
(time interval in minutes between when the specimen was removed from the blood supply and 
the initial placement in formalin); whether the cold ischemic time was 60 minutes or less; 
documentation of the total time the specimen spent in formalin, expressed in hours; whether the 
total time the specimen remained in formalin was within the range of a minimum of six hours 
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and a maximum of seventy-two hours.  A benchmark of 90% will be utilized to measure 
compliance, as 90% is the benchmark used by the College of American Pathologists in 
certification of pathology laboratories, (2013).  The last quality indicator will be the Her-2/neu 
positivity rate, which is currently 15 – 20% (Wolf et al., 2013).   
As a result of this project, we expect to improve safety and accuracy by decreasing the 
risk of false negative or false positive test results for biomarkers specific to breast cancer, which 
include estrogen receptors, progesterone receptors and Her-2/neu receptor amplification.  We 
expect to improve timeliness by decreasing the cold ischemic time and the total time the 
specimen remains in formalin.  Documentation of the critical times used by pathologists to 
determine compliance with ASCO/CAP Guidelines will also be improved, along with 
compliance with ASCO/CAP Guidelines.  A benchmark of 90% or above has been set for each 
indicator.  Cost will also be reduced by decreasing the number of tests for biomarkers performed 
on core biopsy specimens, and then repeated on the definitive surgical specimen.   
 Statement of the Problem  
Problem Statement 
Improper specimen collection and handling procedures are a safety and quality issue, and 
national guidelines have been developed to prevent inaccurate test results, prevent harm to 
patients and to certify pathology laboratories.   
A problem with breast cancer specimens being placed in formalin in a timely manner 
consistent with ASCO/CAP Guidelines was identified.  In addition, documentation of the critical 
times and information necessary for pathologists to determine if specimens had been handled in 
compliance with guidelines were inconsistent.  In order to prevent false negative or false positive 
biomarker test results, a thorough review of the process of breast cancer specimen collection and 
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handling was initiated.  We investigated possible causes and contributing factors of the problem, 
followed by interventions to correct the process, and identified necessary changes to the policy 
and procedure to ensure breast cancer specimens are collected and handled consistent with 
ASCO/CAP Guidelines.   
          Project Overview 
Background 
In 2014, several incidences occurred to bring problems with the collection and handling 
of breast cancer specimens to the forefront.  The first incident was a casual comment from a 
breast surgeon expressing her frustration with a delay in breast cancer specimens being prepared 
for and transferred to the pathology department in a timely manner without her directing the 
surgical team to place the specimen in formalin.  The next impetus occurred at a dinner and 
presentation on Breast Cancer and Biomarkers sponsored by Genentech and given by an 
Advanced Oncology Certified Nurse and Clinical Nurse Specialist through the California East 
Bay Oncology Nursing Society (CEBONS), our local chapter for the Oncology Nursing Society.  
During her talk, one slide addressed the importance of proper breast cancer specimen collection 
and handling which referenced the most current guidelines.  The CNS also mentioned that a 
delay in fixation and/or under-exposure or over-exposure to formalin could cause positive or 
false negative results of the biomarker tests that are performed on every breast cancer specimen, 
and are used to determine a patient’s systemic therapy.  This was new information, and in light 
of the recent report of delays in breast cancer specimen collection and handling within the health 
system, the importance of looking into the issue was raised.  The last was a serious incident 
report that came from one of four surgical sites within the health system that detailed a major 
breech in procedure which lead to a surgical specimen remaining in an operating room from a 
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Friday afternoon until it was discovered on Monday morning.  The surgical specimen had not 
been placed in formalin, and was seriously degraded.  Although the specimen was not a breast 
cancer specimen, such a breech in procedure caused concern for all specimens and warranted 
additional information to determine the scope of the problem and how it might affect patients 
with breast cancer, my cohort of patients.  The incidents led to further inquiry, multidisciplinary 
team formation and a quality improvement project as described below.     
Confirmation of the Problem 
Following the three incidents that focused attention on a problem with breast cancer 
specimen collection and handing, the issue was discussed at the Breast Health Services Core 
Team Meeting, which meets weekly to discuss program planning, patient issues, quality 
improvement and any other concerns that affect breast health, breast cancer patients and/or 
Breast Health Services.  The Core Team consists of three nurses, one physician and a Certified 
Cancer Registrar.  Respectively, their positions are, the Executive Director of the Oncology 
Service Line, the Nurse Practitioner for Breast Health Services, the Nurse Navigator for Breast 
Health Services, the Medical Director of Breast Health Services, and the Manager of Cancer 
Registry.  Before proceeding with an expensive and time consuming quality improvement 
project, the Core Team wanted additional confirmation of an ongoing problem versus isolated 
incidents.   To obtain additional evidence, it was decided that the Medical Director would discuss 
the issue further with other surgeons and pathologists, and the Nurse Navigator was tasked with 
obtaining feedback from several surgical nurses from each of the four surgical sites.  The Nurse 
Navigator was also asked to perform a spot check of a minimum of ten charts of patients who 
had undergone definitive surgery for breast cancer.  The Medical Director discussed the issue 
with several other breast surgeons and the Medical Director of Pathology.  Two of the three 
BREAST CANCER SPECIMEN COLLECTION 9 
surgeons confirmed delays in breast cancer specimens placed in formalin, and the pathologist 
confirmed the delays and also reported issues with documentation of the essential times 
necessary to calculate the cold ischemic time, which is required for compliance with ASCO/CAP 
Guidelines (Wolff et al., 2013).  Discussions with four surgical nurses revealed that although 
each of the nurses knew the importance of placing specimens in formalin early, only one of the 
four nurses were able to state a time interval of less than one hour and none of the four nurses 
were able to state the rationale for doing so.  The results of the retrospective audit of ten patient 
charts are discussed in depth in the rationale section of this report.  However, the results also 
confirmed a need to proceed with a quality improvement project. 
The First PDSA Cycle 
 The planning phase of the first PDSA cycle was done by the Breast Health Services Core 
Team, with input from additional surgeons, a pathologist and surgical nurses.  The do phase of 
the first PDSA cycle was the spot check of ten consecutive charts of patients who had either 
undergone mastectomy or lumpectomy for breast cancer and the collection of data.  The 
indicators for the first PDSA cycle were also measured in the second and third PDSA cycles, 
however addition indicators were added in the subsequent cycles.  Criteria for the second and 
third PDSA cycles are discussed in goals and objectives.  The three criteria for the first PDSA 
cycle were:  Documentation of the time the specimen was removed from the blood supply, 
documentation of the time the specimen was placed in formalin and the cold ischemic time.  The 
cold ischemic time is defined as the interval time, expressed in minutes, between when the 
specimen was removed from the blood supply and the time the specimen was initially placed in 
formalin (Hammond et al., 2010).  To comply with ASCO/CAP Guidelines, the cold ischemic 
time should be 60 minutes or under (College of American Pathologists, 2013).  A benchmark of 
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90% was set for each of the three indicators and it was decided that if a benchmark of 90% or 
above was found, the quality improvement study would not proceed.  If the results for any of the 
three indicators were below 90%, a multidisciplinary task force would be assembled, and a full 
quality improvement study would be performed.  The data results and analysis is discussed 
thoroughly in the rationale section.  The results for all three indicators were under 90% and a 
more comprehensive multidisciplinary team was formed to review and analyze the data and plan 
the next steps and interventions.   
Multidisciplinary Team Review 
Prior to this project, Breast Health Services had an existing multidisciplinary team that 
met approximately six to ten times a year to guide program development, quality control and 
compliance with standards for accreditation through the National Accreditation Program for 
Breast Centers, (NAPBC).  For this project, a decision was made to expand this team by adding 
key stakeholders from pathology and the surgical facilities, which included a pathologist, 
surgical nurses and representatives from management.  This team, the Breast Cancer Specimen 
Collection & Handling Task Force met on February 18, 2014.  After presentation of the 
background information, (information gathered through informal interviews and the data 
gathered from the first retrospective chart audit), a comprehensive discussion ensued.  From that 
discussion, the multidisciplinary team concluded that the primary cause of problems with breast 
cancer specimen collection and handling was due to a large turnover in surgical nursing staff and 
a high percentage of new nurses in the department for less than one year.  The task force 
recommended mandatory education on specimen collection, handling and adherence to 
ASCO/CAP Guidelines for all surgical nursing staff in all inpatient and outpatient surgical 
settings, review and update of the policy and procedures for all inpatient and outpatient surgical 
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settings, and a second retrospective chart audit of one-month’s breast cancer surgeries to be 
performed after all nursing education sessions were completed.  A Fishbone diagram was created 
based on the discussion and findings of the Task Force meeting, and it is included in appendix A.  
Four mandatory nursing in-services were conducted between July 21, 2014 and July 25, 2014 at 
the Walnut Creek and Concord campuses.  On the Walnut Creek Campus, two in-services were 
conducted, one for the nurses that worked in the inpatient surgery department, and one for the 
outpatient surgery center.  On the Concord Campus, the in-services were designed to 
accommodate both nurses that worked in in-patient and out-patient surgery areas.  Two in-
services were conducted, one for nurses that worked in the mornings, and one for nurses who 
worked in the evenings.  A total of eighty-six nurses attended the mandatory educational in-
services.   
The Second PDSA Cycle  
Following the mandatory in-services for nurses, the multidisciplinary team had planned 
for a retrospective chart audit of an entire month of surgeries and expanded the criteria.  The 
project plan was written on January 29, 2015.  The retrospective chart audit and data collection 
began on February 9, 2015 and was completed on April 14, 2015.  Data analysis and review by 
the Breast Program Leadership Committee occurred between April 16 through April 24, 2015. 
 Although improvements were seen in the indicators measured in the second PDSA cycle 
when compared to the results from the first PDSA cycle, not all of the criteria met the 90% 
benchmark.  The findings, which will be discussed in the rationale section were submitted in a 
report on April 29, 2015. The report included the team’s plan for an intervention and a third 
PDSA cycle, because the benchmark of 90% was not met for all the indicators.  Since the data 
collected in the second PDSA cycle indicated a possible knowledge deficit among physicians, an 
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educational seminar for surgeons, pathologists and the entire breast health services team was 
planned.  Arrangements with Genentech to sponsor a dinner webinar on Specimen Collection, 
Handling & Adherence to ASCO/CAP Guidelines was planned and presented by David G. 
Hicks, M.D., an expert in Pathology and primary contributor in the development of the National 
guidelines.  The webinar along with a discussion for improving the process for breast cancer 
specimen collection, handling and adherence to ASCO/CAP Guidelines occurred on September 
17, 2015.  Soon after the webinar, the plan for the third PDSA Cycle was initiated.   
The Third PDSA Cycle 
The criteria and benchmarks for the third PDSA Cycle were the same as the second 
PDSA cycle as was the plan.  The retrospective chart audit and data collection began on 
February 1, 2016 and was completed on March 15, 2016.  Although the data has been collected, 
the data has not been analyzed or reviewed by the multidisciplinary team.  The Breast Program 
Leadership Committee is scheduled to review and analyze the data on April 20, 2016, at which 
time, either a plan to formalize changes or another intervention will be initiated.   
Goals and Objectives 
We aim to improve the timeliness, accuracy, documentation and compliance with 
ASCO/CAP Guidelines in the collection and handling of breast cancer specimens removed 
during surgery at all surgical sites within the John Muir Health System. 
The process begins with the removal of the specimen from the blood supply, orientation 
of the specimen by the surgeon, by marking the superior, posterior and other borders of the 
specimen with sutures and/or pins, handoff to a surgical nurse in the surgery department or 
outpatient surgery center, who documents the time of removal, places the specimen in a 
container of formalin, labels the specimen contain with patient identifiers and documents the 
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time the specimen was placed in formalin on a form that accompanies the specimen to pathology.   
The specimen is transferred to the pathology department.  The pathologist then marks between 
four to six margins of the specimen with different colors of dye to ensure that the location of any 
positive margins can be identified.  The specimen is then serially sectioned to enhance fixation, 
and again placed in formalin for a minimum of six hours and not more than seventy-two hours.  
The process ends with the microscopic evaluation and diagnosis by a JMH pathologist and 
documentation of the cold ischemic time and the total time the specimen spent in formalin in the 
pathology report.     
By working on the process, we expect to improve timeliness and efficiency by decreasing 
the time interval from when the specimen is removed from the blood supply until it is initially 
placed in formalin.  The time that specimens will be placed in formalin will not exceed 60 
minutes in 90% of specimens, and breast cancer specimens will remain in formalin for at least 
six hours and not to exceed seventy-two hours for 90% of specimens, based on ASCO/CAP 
Guidelines (Wolff et al, 2013). 
We expect to improve documentation of the time the specimen was removed from the 
blood supply and the time the specimen was placed in formalin in a minimum of 90% of 
specimens.  In addition, the cold ischemic time and the total time the specimen spent in formalin 
will be recorded on a minimum of 90% of all pathology reports.   
 Safety will be improved by prevention of false positive or false negative results of 
biomarkers for breast cancer, which include immunohistochemical results for estrogen receptors, 
progesterone receptors (Hammond et al., 2010). and HER-2/neu receptor amplification (Hicks & 
Schiffhauer, 2011). False positive or false negative results will be prevented by compliance with 
the time frames established by ASCO and CAP to prevent under or over exposure in formalin in 
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a minimum of 90% of specimens. The rate of invasive breast cancers that test positive for Her-
2/neu amplification will be consistent with the National rate of Her-2/neu positivity, which is 
currently 15 – 20%. 
Cost will be reduced in the third PDSA cycle by eliminating redundant testing of 
immunohistochemical assays for estrogen receptors, progesterone receptors and HER-2/neu 
receptors and/or fluorescence in situ hybridization, (FISH).  Before the third PDSA cycle, these 
tests were performed on the core biopsy specimen at the time of diagnosis, and repeated on the 
definitive surgical specimen.  As a result of the comprehensive literature review and 
multidisciplinary discussion with David G. Hicks, M.D., in the second PDSA Cycle, a decision 
was made to perform these tests for biomarkers on definitive surgical specimens only beginning 
January 1, 2016.  A decision that tests for biomarkers on core biopsy specimens would not 
routinely be performed, and only done if ordered by a physician or requested at Breast Tumor 
Board.  Through compliance with ASCO/CAP Guidelines, cost can also be lowered by reducing 
the number of equivocal test results, which require additional, more expensive tests, such as 
FISH.  Equivocal test results can be caused by over exposure of the specimen in formalin.  By 
adhering to guidelines that limit formalin exposure to a maximum of seventy-two hours, 
equivocal test results can be reduced.  
Quality Improvement Project Plan 
The Breast Cancer Specimen Collection, Handling & Adherence to ASCO/CAP 
Guidelines project has three separate PDSA cycles.  The project overview and rationale contain 
additional information about the impetus and actions prior to the initiation of the study.   
Therefore, the project plan begins with the multidisciplinary team formation.  After the 
multidisciplinary team established the goals and objectives and determined the criteria and 
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benchmarks, a plan for a retrospective chart audit and data collection, followed by data review 
and data analysis in each of the three PDSA Cycles.  Interventions based on the data analysis 
would follow, and the PDSA cycles would repeat until all benchmarks were met at 90% or 
above.  We aim to improve the timeliness, accuracy, documentation and compliance with 
ASCO/CAP Guidelines in the collection and handling of breast cancer specimens removed 
during surgery at all surgical sites within the John Muir Health System.  In addition, a cost 
savings component was identified in the second PDSA Cycle and implemented in the third 
PDSA Cycle.  This first PDSA Cycle began in early 2014 and the project will continue until all 
criteria meet or exceed the benchmark of 90%.   We are currently at the end of the data collection 
phase in the third PDSA Cycle.  Data analysis by the multidisciplinary team is scheduled for 
April 20, 2016.  Additional interventions will then be planned or a plan for sustainability will be 
created, depending on the data analysis results.   
Specific Aim Statement 
 
The global aim of this project is to improve safety, timeliness, accuracy, documentation 
and compliance with ASCO/CAP Guidelines in the collection and handling of breast cancer 
specimens removed during surgery at all inpatient and outpatient surgical sites within the John 
Muir Health System in 90% of cases or above by December 31, 2016.  
The specific aim statement is to monitor the documentation of critical times and the 
process of breast cancer specimen collection and handling through PDSA Cycles with planned 
interventions in each cycle that will ensure compliance with ASCO/CAP Guidelines in all four 
surgical sites within John Muir Health by December 31, 2016.  By completing the PDSA Cycles, 
planned interventions and improving the process of breast cancer specimen collection and 
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handling to be consistent with ASCO/CAP Guidelines, we will achieve our specific and global 
aim statements.   
Rationale 
Needs Assessment 
As described more thoroughly in the background of this paper, three incidences were the 
impetus for this quality improvement project, which were an initial report from a breast surgeon 
of a delay in specimens being placed in formalin, an unanticipated acquisition of knowledge 
regarding the importance of timeliness of placing specimens in formalin and the potential effects 
if they were not, followed by a serious incident report of a surgical specimen not placed in 
formalin and left in a surgical suite from Friday through Monday.    
Following these three incidents that focused attention on a problem with breast cancer 
specimen collection and handing, it was necessary to confirm there was a problem with the 
process or whether the incidences were isolated.  Confirmation of a problem was accomplished 
through interviews with surgeons, a lead pathologist and surgical nurses.  Two of the three other 
surgeons confirmed delays in breast cancer specimens placed in formalin, and the pathologist 
confirmed the delays and also reported issues with documentation of the essential times 
necessary to calculate the cold ischemic time, which is required for compliance with ASCO/CAP 
Guidelines (Wolff et al., 2013).  Discussions with four surgical nurses revealed that although 
each of the nurses knew the importance of placing specimens in formalin early, only one of the 
four nurses was able to state a time interval of less than one hour and none of the four nurses 
were able to state the rationale for doing so.   
The interviews were followed by a retrospective chart audit of ten patient charts who had 
undergone definitive surgery for breast cancer in January, 2014.  The first ten consecutive 
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definitive surgeries that were performed in January, 2014 were selected for retrospective chart 
audit.    The criteria for the first PDSA cycle included the time the specimen was removed from 
the blood supply, the time the specimen was placed in formalin and the cold ischemic time, 
which is the interval time between the time the specimen was removed from the blood supply 
and the time the specimen was initially placed in formalin, which was calculated in minutes.  A 
benchmark of 90% was set for each of the three indicators, and the maximum time allowed for 
the interval between time the specimen was removed from the blood supply until it was placed in 
formalin was 60 minutes, which is consistent with ASCO/CAP Guidelines (Wolff et al, 2013).  
The data collected for this indicator was expressed in minutes.  The retrospective chart audit 
results were as follows:  The time the specimen was removed from the body was documented in 
seven out of ten charts, or 70%.  The time the specimen was placed in formalin was documented 
in six out of 10 charts, or 60%.  Therefore, the cold ischemic time could only be calculated in 
60% of the specimens.  Out of the six charts in which there was documentation of the times 
necessary to calculate the cold ischemic time, four of the six times met the benchmark of under 
60 minutes, or 66%.  The cold ischemic time, which again should be 60 minutes or less, ranged 
from 33 minutes to 79 minutes, and the average was 54 minutes.  The benchmark of 90% was 
not met for any of the criteria, which was additional confirmation of a problem and justification 
for a quality improvement project. 
Fishbone Diagram   
During the first PDSA Cycle, a Fishbone Diagram was created from the information 
obtained from the interviews, particularly with nurses.  The Fishbone Diagram for the Breast 
Cancer Specimen Collection & Handling Study is featured in Appendix A.  The causes and 
contributing factors were divided into the following categories. 
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Process. During the evaluation of the process of breast cancer specimen collection and 
handling in the four different surgery sites, it was clear that there was no standardization of the 
process.  There were four different policy and procedures, none of which were specific to breast 
cancer and all the policy and procedures were outdated and not based on current evidence.  
Environment.  The environments in all four surgical sites were of course all different.  
Some of the environments had space for storage of some supplies in the OR, but nurses shared 
that one of the biggest reasons for a delay in placing specimens in formalin is that the containers 
and formalin were kept outside of the OR and unless they were brought into the OR in advance 
of the surgery, placing the specimen in formalin usually was done after the surgery was 
complete. 
People. The multidisciplinary team with input from surgical services management 
concluded that there had been a large turnover in nursing staff, especially in the outpatient 
surgery sites.  There were a large number of new nurses with minimal experience and there had 
been a loss of experienced nurses that had been mentors to newer nurses due to retirement. 
Equipment & Supplies.  In assessing equipment and supplies, proximity and access to 
supplies was again mentioned.  Nurses also shared that it was difficult to plan ahead and gather 
the container and formalin prior to surgery because the size of the specimen is unknown, and 
specimens must be placed in a container that allows complete coverage with a 10:1 ratio between 
formalin to breast tissue specimen.    
Management.  The most obvious variable regarding management was that there were 
four different managers.  Most of which were open to multidisciplinary review and change, but 
at least one that was resistant to the process.   
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Measurement. The retrospective chart audit in the first PSDA Cycle concluded that only 
66% of specimens were placed in formalin within 60 minutes.  In addition, the time the specimen 
was removed from the blood supply was only recorded in 70% of cases, and the time the 
specimen was placed in formalin was only recorded in 60% of cases. 
SWOT Analysis 
A SWOT Analysis of the Specimen Collection, Handling & Compliance with CAP Guidelines 
revealed the following strengths, weaknesses, opportunities and threats.   
Strengths.  One of the strengths of the project is volume.  Because there are over one-
hundred mastectomies performed and approximately four hundred and fifty lumpectomies for 
breast cancer performed a year within the health system, this project has the potential to impact a 
large number of patients.  The health system places a high priority on quality care.  They 
participate in MediCare’s program for Accountable Care Organizations, they have Magnet 
Certification on both their Walnut Creek and Concord Campuses and administration is highly 
supportive of this quality improvement project.  Multidisciplinary participation by all 
stakeholders will improve the likelihood that this project will be successful and is another 
strength of the project.  By including all surgical sites, both inpatient and outpatient, it will also 
allow us to standardize the policy and procedure for breast cancer specimen collection, handling 
and compliance with national guidelines throughout the health system.  In addition, the project 
will improve our specimen collection and handling process, minimize errors in test results due to 
under or over fixation of specimens and therefore deliver safer care to patients (Koury, Sait & 
Hwang, 2009).  We will be able to improve timeliness and efficiency with placement of breast 
cancer specimens in formalin sooner, and we will be able to eliminate duplicate testing for 
estrogen receptors, progesterone receptors and Her-2/Neu receptor amplification, which were 
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being performed on core biopsies and then repeated on the specimen from the patient’s definitive 
surgery in most cases.  Due to the heterogeneous nature of tumors, immunohistochemical assays 
on core biopsies are much more likely to be false positive or negative, and for most patients, 
these tests should be run on the definitive specimen (Potts, Krueger & Landis, 2012). 
Weaknesses.  A weakness, or challenge of the project is that we will be attempting to 
standardize a process in four surgical settings, two outpatient centers and two inpatient surgical 
units with different management, diverse cultures and a considerable difference in what is 
required between the inpatient and outpatient settings.  There is also a higher percentage of 
newer nurses in the outpatient surgical areas when compared to the inpatient units, and higher 
turnover rates, which have the potential to affect the project.  Access to formalin has also been 
identified as a weakness, as it is a carcinogen and must be stored in specific conditions and 
exposure must be limited to meet federal safety standards (OSHA, 2016).  Therefore, storage is 
almost always away from the operating rooms and nurses must either prepare for specimen 
collection before the surgery or wait until after the surgery is over. This has the potential to effect 
timely placement of breast cancer specimens in formalin.  Sustaining change has been identified 
as a potential weakness.   
Opportunities.  Opportunities include standardizing one policy and procedure for the 
health system, creating a policy and procedure that is evidence-based, potentially adding to 
existing literature, identifying champions or Nurse Leaders at each surgical site in an effort to 
ensure sustainability, utilizing the electronic health record to document the time the specimen is 
removed from the blood supply and the time the specimen is placed in formalin and adding a 
hard stop in the electronic health record to ensure these critical times are recorded by nursing. 
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Threats.  Threats include workarounds, a drift back to non-compliance with ASCO/CAP 
guidelines and buy-in by surgical management, surgeons and nurses to change.  Pathologists 
must also be willing to discuss coverage on weekends so that surgeries performed on Thursdays 
and Fridays do not exceed the 72 hour limit of specimens remaining in formalin, which has the 
potential to alter test results (Yildiz-Aktas, Dabbs & Bhargava, 2012).  
Cost Analysis 
While there should be no difference in cost associated with specimen collection and 
handling consistent with National guidelines, there is considerable costs when performance 
needs to be measured and evaluated.  In addition, the costs associated with assembling a team 
that involves multiple disciplines and departments, and implementing training programs can 
become excessive. 
The costs of this project have been separated into costs per PDSA Cycle.  There are two 
teams that met and continue to meet associated with this project, a small group that consists of 
the medical director, the executive director, nurse practitioner, cancer registry manager and the 
Nurse Navigator/CNL student. The cost associated with this meeting is $525.00. This group 
meets approximately twice a month.  Six meetings occur per cycle, for a total of eighteen 
meetings, at a cost of $9,450.00. The second team is an interdisciplinary team with members 
from multiple departments. This group has met once during this cycle of the project, and it will 
meet once more in April for data analysis and planning for implementation of improvements. 
Some of the physicians on this team are not contracted with the hospital and receive no 
compensation for time spent on the team. The cost of physicians contracted with the hospital and 
employees per meeting is $1,650.00. Therefore, the entire cost of the interdisciplinary team is 
$9,900.00. 
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The other main cost of this project is the time spent on chart audits and nursing time 
coordinating the project. Nursing time was 28 hours in the first PDSA Cycle and 34 hours in the 
second PDSA Cycle.  To date in the third PDSA Cycle, nursing time has been 14 hours, and 
another 16 hours are anticipated, for a total cost of $6,900.00 for nursing time associated with the 
project.   
In the first cycle of this project, a mandatory in-service was required for all surgical 
nurses at three of the surgical sites. Paid time for the 86 nurses that attended the in-service 
totaled $5,590.00. Additional office related costs associated with the in-services that included 
refreshments for staff at a cost of $550.00 and miscellaneous handouts and printing at $75.00. In 
the second cycle of the project a dinner and webinar presentation for all the pathologists, 
surgeons and other physicians and team members involved was given at Ruth Chris Steakhouse, 
with an expert in pathology, David Hicks, M.D. Forty-one physicians attended the dinner. 
Because proper specimen collection and handling is essential to selecting treatment for women 
with breast cancer, we approached Genetech, who underwrote the cost for the dinner and 
speaker. Office supplies in the second cycle cost $150.00, and approximately $75.00 to date in 
the 3rd cycle, for a total cost of $300.00. The cost of the entire CQI study is projected to cost 
$32,890.00. 
One unanticipated result of this project that came about because of the literature review 
and a vigorous discussion at the webinar dinner with Dr. Hicks in September, 2015 was whether 
testing for estrogen receptors, progesterone receptors and Her-2/neu biomarkers by IHC should 
be done on the core biopsy vs. the definitive specimen. Ordering physicians wanted the testing 
done on the core biopsy, but these tests were usually repeated on the definitive surgical specimen 
because of the heterogeneity of cancer and the inability to see variations in small, core biopsy 
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specimens. The costs for estrogen receptor testing by IHC is $167.00. The cost for progesterone 
receptor testing by IHC is $168.00, and the cost for Her-2/neu by IHC is also $167.00. When 
Her-2/neu is testing by flourescense in situ hybirdization, (FISH) is also performed due to 
equivocal results, the cost is $375.00. These are considerable redundant costs, and at the 
meeting, it was decided that these tests would not be routinely run on the core biopsy specimens, 
unless specifically ordered by the physician beginning January 1, 2016. Over 700 patients are 
diagnosed and treated for breast cancer at John Muir Health per year. To be conservative about 
the savings due to this change in practice, we estimated that approximately 400 of those cases 
would only have testing done on the definitive specimen, and 300 specimens would still have 
redundant testing due to orders by physicians who want earlier access to the results for treatment 
planning.  This project would conservatively eliminate 400 redundant tests for estrogen 
receptors, 400 redundant tests for progesterone receptors, and 400 redundant tests for Her-2/neu 
amplification by IHC. Since some specimens are tested by IHC and some require additional 
testing by FISH. We estimated approximately one-quarter of the 400 patients would require the 
additional testing. Based on these estimates, the savings due to the elimination of redundant tests 
would be $238,550.00 in one year. A plan is in place to calculate the actual savings for 2016. 
The estimated cost benefit for this project is estimated at $205,660.00.  A detailed Projected Cost 
Analysis & Cost Benefits Analysis is depicted in Table 1 in Appendix F. 
Data Sources 
 In summary, the data and information that was used to justify this quality improvement 
project included verbal reports of a problem, incident reports, interviews with stakeholders, data 
from chart audits, multidisciplinary discussions and data analysis, review of the policy and 
procedures, literature review, Fishbone Analysis (Appendix A), Process Mapping (Appendix B), 
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SWOT Analysis (Appendix C) and Stakeholder Analysis (Appendix D).  After the second PDSA 
Cycle, a cost analysis and cost benefits analysis were performed, (Appendix E & F).  The 
timeline for the project is documented in a Gantt chart (Appendix G).  In addition, Appendix H is 
a link to a FMEA tool that was utilized for this project and published on the Institute for 
Healthcare Improvement (IHI) website (IHI, 2015). 
 
Methodology 
 
Approach 
 
The Breast Cancer Specimen Collection & Handling quality improvement project 
consists of three PDSA Cycles.  Each PDSA cycle has a planning phase with a multidisciplinary 
team, a retrospective chart audit and data collection phase, multidisciplinary team review of the 
data, data analysis and planning of next steps, with a minimum of one intervention in each of the 
PDSA cycles and a subsequent plan for follow-up.  The last PDSA Cycle will end with a plan for 
sustainability.  The methodology is best described for each of the PDSA Cycles.   
The first PDSA Cycle   
The first cycle began in early 2014 when a problem with breast cancer specimen 
collection and handling was first identified.  Confirmation of a problem occurred through 
interviews, data collection and analysis.  The data collection phase of the first PDSA cycle 
consisted of selection of ten consecutive breast cancer cases in which the patient had undergone 
either mastectomy or lumpectomy from the January, 2014 surgery schedules with inclusion of a 
minimum of two surgeries from each of the four surgical sites, also chosen consecutively.  A 
retrospective chart audit was then performed and data was collected on three criteria:  
Documentation of the time the specimen was removed from the blood supply, documentation of 
the time the specimen was placed in formalin and the interval time in minutes between the 
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removal from the blood supply and placement in formalin, also known as the cold ischemic time.  
The benchmark used for documentation of times was 90% and the benchmark for the cold 
ischemic time was 60 minutes, which is consistent with ASCO/CAP Guidelines (Wolff et al., 
2013).   
The First PDSA Cycle Data Analysis.  Following the retrospective chart audit, the 
percentages for each of the three criteria were calculated, resulting in the following findings.  
The time the specimen was removed from the blood supply was recorded in seven of the ten 
charts, or 70%.  The time the specimen was placed in formalin was recorded in six of the ten 
charts, or 60%, and out of the six cases in which the cold ischemic time could be calculated, four 
were placed in formalin within 60 minutes, or 66% of specimens were placed in formalin within 
60 minutes.  None of the three criteria met the benchmark of 90%, which was justification to 
proceed with the quality improvement project. 
The second PDSA Cycle   
For the second PDSA cycle, the project was revised and the criteria were expanded.  The 
study was rewritten on January 29, 2015.  The criteria for the second PDSA Cycle included:  
Time the specimen was removed from the body.  Time the specimen was initially placed in 
formalin.  Time the specimen was sent to pathology and the interval time in minutes between the 
removal from the blood supply and placement in formalin, the percentage of cases in which the 
cold ischemic time was under 60 minutes, and the total number of hours the specimen remained 
in formalin before analysis by the pathologist.  The benchmark for the following criteria was set 
at 90%.  To calculate the interval times in minutes or hours, an application was utilized, 
timeanddate.com.  In addition, the percentage of cases that were Her-2/neu positive was also 
calculated and compared to National averages, which is currently 15 – 20% (Wolff et al., 2013).  
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Her-2/neu is not currently measured for in situ cases, so all stage 0, ductal carcinoma in situ 
cases were excluded from the Her-2/neu positivity calculation.   
In an effort to ensure that cases were selected similarly for all PDSA cycles, the 
following strategy was utilized.  Lists of patients diagnosed with breast cancer in October, 2014 
were obtained from Cancer Registry and Medical Imaging.  The lists were merged and duplicates 
were eliminated.  There were fifty-one patients identified for the second PDSA cycle. Cases in 
which the surgeries were not definitive, either mastectomy or lumpectomy, were excluded.  
Excluded cases were surgeries for re-excision, reconstruction and axillary lymph node dissection 
only.  After the elimination of eleven cases that did not meet the selection criteria, forty cases 
remained, which was the denominator for the second PDSA Cycle.   
The retrospective chart audit and data collection portion of the second PDSA Cycle 
began on February 9, 2015 and was completed on April 14, 2015.  Data analysis and review by 
the multidisciplinary, Breast Program Leadership Committee occurred between April 16 through 
April 24, 2015 and the findings were submitted in a report on April 29, 2015.  The report 
included the team’s plan for an intervention and a third PDSA cycle.  A third PDSA cycle was 
necessary because although improvements were seen in the indicators, not all of the criteria met 
the 90% benchmark. Since the data collected in the second PDSA cycle indicated a possible 
knowledge deficit among physicians, an educational seminar for surgeons, pathologists and the 
entire breast health services team was planned.  Arrangements with Genentech to sponsor a 
dinner webinar on Specimen Collection, Handling & Adherence to ASCO/CAP Guidelines was 
planned and presented by David G. Hicks, M.D., an expert in pathology and primary contributor 
in the development of the National guidelines.  The webinar along with a discussion on 
improving the process for breast cancer specimen collection, handling and adherence to 
BREAST CANCER SPECIMEN COLLECTION 27 
ASCO/CAP Guidelines occurred on September 29, 2015.  Due to the fact that the benchmark of 
90% for all of the criteria were not accomplished for all the indicators, a third PDSA cycle was 
planned. 
The Second PDSA Cycle Data Analysis.  There were forty charts of breast cancer 
patients that underwent definitive surgery and required a comprehensive chart audit.  The data 
collected showed that the time the specimen removed from the body was recorded in thirty-five 
out of forty charts, or 87.5%.  This is under the 90% benchmark and required multidisciplinary 
review.  While looking for patterns, four out of five of the surgeries that did not have a time of 
removal were performed by one surgeon.   Documentation of the time the specimen was placed 
in formalin was present in thirty-two of the forty charts, or 80%, which is also under the 90% 
benchmark and needs multidisciplinary review.  The cold ischemic time could be calculated in 
thirty-three of the forty charts, or 82.5%.  It was noted that all seven surgeries in which the cold 
ischemic time was not documented were performed by two surgeons.  The cold ischemic times in 
thirty-two of thirty-three cases were within sixty minutes or less, or 97%, which exceeds the 
benchmark of 90%.  One case had a cold ischemic time of sixty-five minutes, slightly over the 
benchmark of sixty minutes.  The actual time the specimen was sent and/or arrived in pathology 
could not be found in the electronic health record (EHR).  On the majority of the pathology 
reports, the time of arrival in pathology was documented at 00:00 on the date of surgery.  The 
actual number of hours that the specimen spent in formalin was also not documented on the 
pathology report or in the EHR.  Instead, the recommended guideline of 6 – 72 hours was 
recorded, making it impossible to calculate the actual warm ischemic time.  Out of the 40 
pathology reports, all but one had a documented warm ischemic time of 6 to 72 hours, with one 
case in which the specimen required new testing due to a prolonged time in formalin that 
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exceeded 72 hours.    Lastly, we calculated the Her-2/neu positivity rate of all the invasive breast 
cancers.  Cases of ductal carcinoma in situ (DCIS) were eliminated from this calculation, as Her-
2/neu testing is not currently performed on specimens of DCIS.  There were 7 of the 40 
specimens that were DCIS only.  Out of the 33 patients who had an invasive breast cancer, 5 
tested positive for Her-2/neu, or 15%, which meets the low range of anticipated Her-2/neu 
positivity of 15 – 20% (Wolff et al., 2013).   
The Third PSDA Cycle 
In an effort to select cases similar to cases reviewed in the second PDSA Cycle, cases for 
the third PDSA Cycle were selected in the same manner as they were in the second PDSA Cycle 
by initially obtaining lists of patients from Cancer Registry and Medical Imaging, merging those 
lists and eliminating duplicates.  The month of study for the third PDSA Cycle was October, 
2015.  After eliminating duplicates, there were fifty-seven identified cases for the third PDSA 
Cycle.  Cases in which the surgeries were not definitive, either mastectomy or lumpectomy, were 
excluded.  Excluded cases were surgeries for re-excision, reconstruction, axillary lymph node 
dissection only and one case was eliminated because no cancer was found in a mastectomy 
specimen following neoadjuvant chemotherapy.   Fifteen of the fifty-seven cases did not meet 
the selection criteria and were excluded, leaving a total of forty-two cases that met the criteria for 
inclusion and a comprehensive chart audit.  The third PDSA cycle of chart audits began on 
February 1, 2016 and was completed on March 15, 2016.  An interval upgrade of the electronic 
health record made the third cycle of data collection more efficient.  In addition to the data 
collection criteria listed below, documentation of basic patient identifiers, the day of the week 
the surgery was performed, the surgeon who performed the surgery and the pathologist were 
documented for the possible identification of patterns.   
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 The criteria for the third PDSA Cycle were the same as the second PDSA Cycle, and 
included:  Time the specimen was removed from the body.  Time the specimen was initially 
placed in formalin.  Time the specimen was sent to pathology and the interval time in minutes 
between the removal from the blood supply and placement in formalin, the percentage of cases in 
which the cold ischemic time was under 60 minutes, and the total number of hours the specimen 
remained in formalin before analysis by the pathologist.  The benchmark for the following 
criteria was set at 90%.  To calculate the interval times in minutes or hours, an application was 
utilized, which was timeanddate.com.  In addition, the percentage of cases that were Her-2/neu 
positive will also be calculated and compared to national averages, which is currently 15 – 20% 
(Wolff et al., 2013).  Her-2/neu is not currently measured for in situ cases, so all stage 0, ductal 
carcinoma in situ cases will be excluded from the Her-2/neu positivity calculation.   
The Third PDSA Cycle Data Analysis.  Although the data collection phase of the third 
PDSA Cycle concluded on March 15, 2016, the data has not undergone multidisciplinary review 
or data analysis, which is scheduled to occur on April 20, 2016.  The results of the data analysis 
will be detailed in the summary of the prospectus.   
Specific Changes 
The changes that will be implemented are to standardize the process, policy and 
procedures across four surgical sites in the health system, and to ensure the changes are 
evidence-based and consistent with ASCO/CAP Guidelines for breast cancer specimen collection 
and handling.  The criteria that will be utilized to measure change are documentation of the time 
the specimen was removed from the body and the time the specimen was initially placed in 
formalin.  In addition, the calculated cold ischemic time will be under 60 minutes (number of 
minutes from excision to placement in formalin), and the total number of hours the specimen 
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remains in formalin before analysis by the pathologist.  A benchmark of 90% will determine if 
the criteria is met or further interventions are required.  For all invasive breast cancer cases 
(excluded in situ cases), the percentage of patients that were Her-2/neu positive will also be 
calculated and compared to National averages, which is currently 15 – 20%.   
Change Theory 
 
The change theory that underpins this quality improvement project is Lewin’s Theory.  
Lewin’s Theory, or the Force Field Model of Change describes a dynamic balance of forces 
working in opposing directions. These forces include driving forces, which move people and 
organizations in the direction of change, restraining forces, which move people and organizations 
against change and equilibrium, a state in which the driving forces and restraining forces are 
equal resulting in no change (Nursing Theory, 2015). 
Driving forces of the Specimen Collection, Handling & Adherence to ASCO/CAP 
Guidelines project include. Sharing of the data analysis that identified areas that were under the 
established benchmark and creating awareness of a problem. Another driving force is 
comparison of our data with established National Guidelines to create a sense of urgency 
regarding the issue. Development of a strong interdisciplinary team with respected members that 
can effect change is also a driving force of the project. 
Restraining forces of the project include selecting a project in which the problem was 
identified incidentally, and had not been identified as an area of high priority. Information on 
how improper specimen collection and handling techniques affect the accuracy of tests utilized 
to decide treatment decisions will help counteract this restraining force, as will the sheer volume 
of patients that could be affected, as breast cancer accounts for approximately one-third of all the 
cancers diagnosed and treated in our health system. Another restraining force is that the project 
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involves multiple disciplines and multiple sites within the health system in which breast cancer 
specimens are collected. Those sites vary in that some are inpatient and some are outpatient, both 
with different leadership, policy and procedures and requirements. In addition, there are a variety 
of ways in which specimens are transferred to pathology, which also has three sites in which 
specimens are analyzed. Including members from every discipline and site in the team and 
effective team leadership skills is our strategy to counteract problems that will effect 
implementation related to this restraining force. Because this project has strong driving force and 
strong restraining forces, there is a risk of equilibrium. Therefore, the implementation process 
must maximize the driving forces and minimize the forces that would restrain it. 
Currently, the Specimen Collection, Handling and Adherence to ASCO CAP Guidelines 
project remains in the unfreezing stage of Lewin’s Theory and will not be completed until after 
analysis of the data collected in the third PDSA cycle.  Although, during this stage we have done 
some of the work in the moving stage.  During the unfreezing stage, we have focused on building 
awareness of the problem and preparing employees for change, we have shared data from the 
first and second PDSA cycles, and we have shared how our data compares with national 
guidelines and benchmarks to raise awareness of the problem. We assembled an initial 
interdisciplinary task force that eventually led to a larger team that has been educated on all 
aspects related to the issue. We have utilized tools to more thoroughly understand the problem, 
which included a SWOT Analysis, Fishbone Diagram, Process Mapping and a Force Field 
Analysis to identify our driving and restraining forces. We have conducted mandatory in-
services for all surgical nursing staff at every site that specimens are collected. To educate our 
surgeons, pathologists and other healthcare professionals that provide services to breast cancer 
patients, we brought in an expert in the pathology of breast cancer, David Hicks, M.D. who is a 
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major contributor to the literature on the issue of specimen collection and handling and who also 
collaborated in the development of the national guidelines. After analysis of the data collected in 
the Third PDSA Cycle, we will determine if our past interventions have improved performance, 
and the results of the data analysis will also be shared with all stakeholders. 
As we transition into the moving stage of Lewin’s Change Theory, which will involve 
implementation of the changes, we have clearly identified the problem, identified the goals and 
objectives, and the multidisciplinary team is scheduled to review the data collected in the third 
PDSA Cycle, analyze the data and write an action plan on April 20, 2016.  Will then initiate that 
action plan and implement the changes.   
The Re-freezing stage will occur after we implement our changes. Since this stage 
includes actions that prevent a return to previous practices, we have anticipated some measures 
that might prevent the process returning back to the status quo. These include gaining consensus 
on a new policy & procedure for the process that works in both the inpatient and outpatient 
settings. Identifying and eliminating any workarounds to the new process and investigating using 
technology to enhance performance, such as bar coding of specimens and creating hard stops in 
the EHR that will not allow a process to move forward if vital information is not entered.  We 
will develop a plan for sustainability, and we anticipate that periodic monitoring of the criteria 
will be necessary to verify that the changes have been incorporated into routine practice.   
Literature Review 
 
Literature Sources 
 
In addition to accessing articles through the Gleeson Library and CINAHL, articles were 
also obtained through Google Scholar, PubMed and MedlinePlus.  
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PICO Search Statement 
 
The following PICO search strategy was utilized for a literature search:   
P: Women with breast cancer undergoing surgery 
I: Fixation of breast cancer specimen tissue in formalin within 60 minutes & documentation of 
the cold ischemic time 
C: Delay in fixation of breast cancer specimens and the effect on biomarker results. 
O: Compliance with CAP/ASCO Guidelines for breast cancer specimen collection & handling.  
This PICO strategy returned numerous articles from journals that were specific to breast 
cancer specimen collection and handling and how improper specimen collection and handling 
procedures effect the quality of the biomarkers used to decide treatment for women with breast 
cancer. However, there were some challenges. The first challenge was that there is not a lot of 
articles written by nurses on the subject. In fact, only two articles authored by nurses were found, 
published in the Journal of PeriOperative Registered Nurses that addressed the nurse’s role in 
proper breast cancer specimen collection and handling. The second challenge was the timeliness 
of the articles.  The first publication of the ASCO/CAP Guidelines was in 2007, and then revised 
guidelines were published in 2013. There was a wealth of interesting and practice-changing 
articles that were published from the 2005 through 2010, that were used as the scientific basis for 
writing the ASCO/CAP Guidelines, but it was challenging to find literature within the 2011 to 
2016 time frame.  
Literature Review from Annotated Bibliography 
In an article on oncogenes by Arteaga & Engelman, (2014), the authors discuss the role 
of the human epidermal growth factor receptor family, also known as the ErbB family, or HER 
family and how their signal pathways drive replication, growth and differentiation.  It further 
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discusses how aberrant signaling pathways influence carcinogenesis.  Within the last five years, 
more understanding of the prominent role of these receptors role in the initiation and 
maintenance of several solid tumors, especially HER-2 amplified breast cancer, has led to the 
development of specific ErbB inhibitors as breast cancer therapies, which has paved the way for 
individualized, targeted treatments for breast cancer. 
An article written by Hammond et al., (2010) describes the process in which a group of 
international experts convened by the American Society of Clinical Oncology and the College of 
American Pathologists conducted a systematic review and evaluation of the literature in 
partnership with Cancer Care Ontario, and published recommendations for optimal 
immunohistochemistry (IHC) testing for estrogen receptors (ER) and progesterone receptors 
(PgR) testing.  In the article, they developed guidelines to improve the accuracy of IHC testing of 
these receptors.  The authors determined that up to 20% of IHC testing for ER/PgR are 
inaccurate, and guidelines to improve accuracy are necessary, as these test results are used as 
predictive markers and to decide treatment for patients with breast cancer.  
In an article written by a panel of experts selected to make recommendations for the 
appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic 
therapy for women with early-stage invasive breast.  Towards this end, the authors performed a 
literature search that included metaanalyses, randomized controlled trials, prospective and 
retrospective studies, and prospective comparative observational studies published from 2006 
through 2014 on the subject of the use of breast cancer biomarkers in determining systemic 
treatment that were published between 2006 through 2014.  The literature search identiﬁed 50 
relevant studies.  The authors had particular interest in outcomes that included overall survival 
and disease-free or recurrence-free survival.  Recommendations were then developed to guide 
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oncologists in the use of specific breast cancer biomarkers in selecting appropriate treatment.  
They recommended that in addition to estrogen and progesterone receptors and human epidermal 
growth factor receptor 2 (HER-2), additional biomarkers that were useful in guiding the selection 
of treatment included the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer 
Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in 
speciﬁc subgroups of breast cancer. However, no biomarker except for estrogen receptor, 
progesterone receptor, and HER-2 were found to guide choices of speciﬁc treatment regimens. 
(Harris et al., 2016).   
An article by Hicks & McCarthy, (2011) on breast cancer predictive factor testing and the 
importance of standardizing tissue handling, argues that with the emerging use of biomarkers in 
making systemic treatment decisions for women with breast cancer, older laboratory practices 
must be updated and standardized to preserve the possible presence of macromolecules that are 
in the tissue.  A discussion of the need to better define specimen handling requirements in an 
effort to improve the quality of specimen samples and ultimately the pathology results. 
Authors, Hicks & Schiffhauer, (2011) discuss the problems with immunohistochemistry, 
(IHC) tests routinely performed on breast cancer specimens in their article on standardized 
assessment of the HER2 status in breast cancer by IHC.  In the article, they discuss problems 
with reproducibility, lack of standardization and poor concordance between laboratories.  Their 
focus was specifically on the current inaccuracy of routine testing for human epidermal growth 
factor receptor 2 (HER2) in specimens from breast cancer patients.  They discuss pre-analytic 
and analytic variables and how they can be minimized, and they introduce a new algorithm for 
test interpretation.  The authors also endorse the guidelines set by the American Society of 
Clinical Oncologists (ASCO), and the College of American Pathologists (CAP), and maintain 
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that as these guidelines are followed, variation in breast cancer pathology results will decrease 
and accuracy will improve.  
An article by Hicks, (2014) on the standardization of tissue handling from the OR to the 
laboratory claims that the process of specimen collection and handling from the OR through the 
delivery of the specimen to the laboratory involves significant patient safety issues and concerns. 
The author maintains that issues are due advances in clinical practice, and a current lack of 
updated knowledge and understanding of what is required to deliver a high quality, optimal 
specimen to the pathology laboratory by perioperative personnel.  The author proposes that 
accurate evaluation of tissue is highly dependent on the quality of specimens, especially when 
targeted cancer therapies are being considered, and particularly with breast cancer.  He claims 
that we are advancing into a new era of individualized cancer care in which molecular analysis of 
specimens are more clinically important, and the accuracy and reliability of the tissue analysis is 
dependent on the quality of the clinical specimens and how they are collected and handled.  He 
maintains that the policies and procedures in many hospitals and clinics are decades old and do 
not consider these clinical advancements.  In the remainder of the article, a review of how they 
implemented a procedural change to comply with new national guidelines at the University of 
Rochester Medical Center in New York is discussed. 
An article by Loi et al., (2011) on uniform collection of biospecimens from neoadjuvant 
breast cancer clinical trials make recommendations for standardizing breast cancer specimen 
collection with particular emphasis to both the type of specimens and timing of their collection 
with the aim of standardizing the collection of high-quality specimens that would be utilized in 
neoadjuvant breast cancer trials.  The neoadjuvant breast cancer trials for which these 
recommendations for uniform breast cancer specimen collection were developed were the Breast 
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International Group (BIG) and the National Cancer Institute-sponsored North American Breast 
Cancer Group (NABCG). In addition to standardizing the process of breast cancer specimen 
collection for specimens associated with these breast cancer trials, the authors proposed that 
standardization would improve the quality of the specimens collected and would enhance and 
allow integration of results obtained from neoadjuvant trials done by several groups.  
In an article on the genetic identification of four main types of breast cancer, the author, 
Park, (2012) describes a major genome study that identified four main subtypes of breast cancer, 
which include Luminal-A, Luminal-B, Triple Negative, Basal-Like & HER-2 Type, which 
exhibit different biological characteristics, behaviors, responses to treatment and clinical 
outcomes.  These subtypes of breast cancer hold promise for the development of tests that predict 
response to treatment, risk of recurrence and new targeted therapies for breast cancer.  The 
author predicts that breast cancer treatment will no longer be based on the location in the body 
were the cancer originated, but instead will be based on genetic characteristics of the breast 
cancer.    
Timeline 
 
The timeline for the Breast Cancer Specimen Collection & Handling Study began in early 
January, 2014 when an initial problem with issues related to timeliness was reported.  An initial 
literature search occurred in early January, 2014 followed by interviews with surgeons, a 
pathologist and surgical nurses in late January & early February, 2014.  A chart audit of 10 
charts was also conducted in February, 2014 and the multidisciplinary team was formed and met 
in mid March, 2014. An intervention was planned, which was mandatory in-services for all 
surgical nurses.  The planning and preparation for these in-services occurred from April through 
July, 2014, and the actual in-services were completed in the week of July 28 – 30, 2014.  A plan 
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for follow-up occurred in November, 2014, which included planning for a second PDSA Cycle 
to begin in 2015.  A comprehensive literature review occurred in early 2015 followed by revision 
of the study on January 29, 2015, which included additional criteria for measurement. The 
retrospective chart audit and data collection began on February 9, 2015 and was completed on 
April 14, 2015.  Data analysis and review by the multidisciplinary, Breast Program Leadership 
Committee occurred between April 16 through April 24, 2015 and the findings were summarized 
in a report on April 29, 2015.  Multidisciplinary team review occurred in May, 2015, which 
resulted in a planned intervention for physician education with focus on breast surgeons and 
pathologists.  Planning for a dinner/webinar occurred from May through July, 2015, but the 
webinar was delayed due to difficulty in securing the expert speaker in the field of breast cancer 
pathology.  The dinner/webinar occurred on September 29, 2015, and in November, 2015 a plan 
to repeat another PDSA Cycle was determined.  No changes were made to the study plan for the 
third PDSA Cycle.  Patients were selected in January, 2016 and the retrospective chart audits and 
data collection began on February 1, 2016 and was completed on March 15, 2016.  The 
multidisciplinary team is scheduled to review the data on April 20, 2016.  Further information on 
activities for each of the PDSA Cycles are included in Appendix G. 
Expected Results 
This Breast Cancer Specimen Collection, Handling and Adherence to ASCO/CAP 
Guidelines is not scheduled to end until all criteria meet the benchmark of 90% or above.  It is 
our hope that the benchmarks will meet or exceed the 90% benchmark in all or most of the 
criteria when the data analysis by the multidisciplinary team on April 20, 2016.  At which time, 
either further interventions will be planned, or a plan to formalize the process, change and 
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standardize the policy and procedures will occur, which will conclude the third PDSA Cycle.  If 
all the benchmarks are met at that time, a plan for sustainability will be written.   
Nursing Relevance 
With the exception of nurses that work in surgical settings, nurses do not usually give a 
lot of thought to how surgical specimens are collected beyond using aseptic technique.  
However, Clinical Nurse Leaders are prepared to identify and respond to problems within their 
microsystem, and anywhere else their cohort of patients are provided healthcare services.  A 
problem with the collection and handling of breast cancer specimens that had a potential to cause 
harm to patients was identified and confirmed.  It was therefore relevant to further investigate the 
issue and initiate interventions to improve the process.   
In the past, breast cancer treatment was based primarily on the site of origin, size of the 
tumor, stage and the estrogen receptor and progesterone receptor status.  As more and more tests 
for breast cancer biomarkers, other receptors such as the human epidermal growth factor receptor 
family, (also known as the ErbB family or HER family) and their signal pathways that drive 
replication, growth and differentiation, (Arteaga & Engelman, 2014) along with genomic assays, 
such as Oncotype DX, MammaPrint and Mammostrat are developed, it is possible to predict 
which breast cancers are more likely to recur, and breast cancer treatment is becoming more 
individualized to treat the specific cancer itself (Breastcancer.org, 2015).  In a major genome 
study, four subtypes of breast cancers have been identified, suggesting that instead of treating 
cancer based on the location in the body where they originated, treatment should be based on the 
genetic characteristics instead (Park, 2012).  This makes the accuracy of these specific tests 
much more important and there is already enough evidence to show that how quickly specimens 
are placed in formalin and how long specimens stay in formalin can affect the results of such 
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tests and may cause false positive, false negative or variations in intensity of the tests if 
established guidelines are not followed.  This makes it imperative that nurses not only 
understand the conditions that can affect the quality of test results, but they must also have a 
knowledge of the guidelines developed for breast cancer specimen collection and handling, and 
nurses must incorporate these guidelines into practice and the care they provide to patients. 
Summary Report 
AIM Statement of Project 
The collection and handling of breast cancer specimens will be timely and consistent with 
guidelines developed by the American Society of Clinical Oncologists, (ASCO) and the College 
of American Pathologists, (CAP) throughout the health system. 
The specific aim statement is to monitor the documentation of critical times and the 
process of breast cancer specimen collection and handling through PDSA Cycles with planned 
interventions in each cycle that will ensure compliance with ASCO/CAP Guidelines in all four 
surgical sites within John Muir Health by December 31, 2016.  The quality indicators that will be 
measured include: 
Documentation of the time the specimen is removed from the blood supply. 
Documentation of the time the specimen is initially placed in formalin. 
Whether or not the cold ischemic time could be calculated. 
The calculated cold ischemic time is sixty minutes or less. 
The total time the specimen remained in formalin is over six hours and less than seventy-two 
hours.   
The benchmark for the above indicators was set at 90%, consistent with ASCO/CAP Guidelines 
(College of American Pathologists, 2013). 
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The Her-2/neu positivity rate will also be calculated to assure that the results are consistent with 
expected rate based on evidence, which is currently 15 – 20% (Wolf et al., 2013). 
By completing the PDSA Cycles and planned interventions we will improve the process of breast 
cancer specimen collection and handling to be consistent with ASCO/CAP Guidelines.   
Population and Setting 
The population for the microsystem is adult women undergoing breast cancer screening 
and diagnostic services and women diagnosed with breast cancer.  Since 1% of breast cancer 
occurs in men (ACS, 2016), occasionally men are also included in the population.  
The macrosystem has two main hospitals, both with Magnet status, and both are listed by 
U.S. News among the top 100 hospitals in America, (2015).   
The microsystem includes breast health services provided throughout the health system, 
which includes two Breast Health Centers, both of which are accredited through the National 
Accreditation Program for Breast Centers.   Within the health system, there are nine breast 
cancer screening and diagnostic sites under the direction of Medical Imaging.  These sites are 
certified as Breast Imaging Centers of Excellence through the American College of Radiology.  
Women who need diagnostic services and women that are diagnosed with breast cancer are also 
seen in multiple departments throughout the health system, including, but not limited to Medical 
Imaging, Nuclear Medicine, two inpatient surgical centers, two outpatient surgical centers two 
Radiation Oncology Departments, one out-patient infusion center and two inpatient oncology 
units.  The areas of the macrosystem that were the primary focus of the Breast Cancer Specimen 
Collection and Handling Project were the two hospital-based surgical units, two out-patient 
surgical centers and the pathology department with labs at each of two hospitals.  
Methods & Materials 
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In an effort to select cases similar to cases reviewed in the second PDSA Cycle, cases for 
the third PDSA Cycle were selected in the same manner as they were in the second PDSA Cycle 
by initially obtaining lists of patients from Cancer Registry and Medical Imaging, merging those 
lists and eliminating duplicates.  The month of study for the third PDSA Cycle was October, 
2015.  After eliminating duplicates, there were fifty-seven identified cases for the third PDSA 
Cycle.  Cases in which the surgeries were not definitive, either mastectomy or lumpectomy, were 
excluded.  Excluded cases were surgeries for re-excision, reconstruction, axillary lymph node 
dissection only and one case was eliminated because no cancer was found in a mastectomy 
specimen following neoadjuvant chemotherapy.   Fifteen of the fifty-seven cases did not meet 
the selection criteria and were excluded, leaving a total of forty-two cases that met the criteria for 
inclusion and a comprehensive chart audit.  The third PDSA cycle of chart audits began on 
February 1, 2016 and was completed on March 15, 2016.  An interval upgrade of the electronic 
health record made the third cycle of data collection more efficient.  In addition to the data 
collection criteria listed below, documentation of basic patient identifiers, the day of the week 
the surgery was performed, the surgeon who performed the surgery and the pathologist were 
documented for the possible identification of patterns.   
 The indicators for the third PDSA Cycle were the same as the second PDSA Cycle, and 
included:  Documentation of the time the specimen was removed from the body.  Documentation 
of the time the specimen was initially placed in formalin.  Documentation of the cold ischemic 
time, (the interval time in minutes between the removal from the blood supply and placement in 
formalin), the percentage of cases in which the cold ischemic time was under 60 minutes, and the 
total number of hours the specimen remained in formalin before analysis by the pathologist.  The 
benchmark for the following criteria remained at 90%.  To calculate the interval times in minutes 
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or hours, an application was utilized, which was timeanddate.com.  In addition, the percentage of 
cases that were Her-2/neu positive were also calculated and compared to national averages, 
which is currently 15 – 20% (Wolff et al., 2013).  Her-2/neu is not currently measured for in situ 
cases, so all stage 0, ductal carcinoma in situ cases were excluded from the Her-2/neu positivity 
calculation.  
Third PDSA Cycle Data Analysis   
There were forty-two cases of breast cancer patients that underwent definitive surgery 
and met the selection criteria for a comprehensive chart audit.  The data collected showed that 
the time the specimen was removed from the body was recorded in forty of forty-two charts, or 
95%.  This was an improvement from 87.5% in the Second PDSA Cycle, and exceeded the 
benchmark of 90%.   
Documentation of the time the specimen was placed in formalin was present in thirty-
eight of the forty-two charts, or 90%, which met the benchmark of 90%, an improvement from 
80% in the Second PDSA Cycle.   
The cold ischemic time could also be calculated in thirty-eight of the forty-two charts, or 
90%.  This was an improvement from 82.5% in the Second PDSA Cycle, and also met the 90% 
benchmark.   
The cold ischemic times in forty-two of forty-two cases were within sixty minutes or less, 
or 100%, which was an improvement from 97% in the Second PDSA Cycle.   
As was the case in the Second PDSA Cycle, the actual number of hours that the specimen 
remained in formalin was not recorded on the pathology reports in the Third PDSA Cycle.  
Instead, the guideline of six to seventy-two hours is included in the pathology reports.  In the 
Third PDSA Cycle, an upgrade in the electronic health record allowed for review of the time the 
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specimen was sent to pathology and the time the specimen arrived in pathology.  In addition, the 
cold ischemic time, and the time the specimen was analyzed by the pathologist are routinely 
recorded within the pathology report.  These times allowed us to calculate an approximate cold 
ischemic time and the approximate total number of hours the specimen spent in formalin when 
actual times were not recorded.   
Out of the forty-two pathology cases, 100% were in formalin longer than six hours, but 
only twenty of the forty-two cases were in formalin for seventy-two hours or less, or 48%. 
Therefore, 52% of the cases did not meet the benchmark. The range for hours spent in formalin 
was from twenty-nine to one hundred and forty-four hours, and the average was eighty-two 
hours.  In looking for patterns, no relationship between the cases that spent excess time in 
formalin could be associated with the assigned surgeon or the assigned pathologist.  However, in 
looking at the days of the week in which the surgery was performed, we determined that twelve 
of the twenty-two cases in which the specimen spent over seventy-two hours in formalin were 
performed on Thursdays, accounting for 55%, and an additional five cases in which the specimen 
spent over seventy-two hours in formalin were performed on Fridays, or 23%.  Since a total of 
78% of the specimens that spent excessive time in formalin were from surgeries performed on a 
Thursday or Friday, we have established that surgeries that occur at the end of the week are at 
higher risk for over-exposure to formalin. 
Lastly, we calculated the Her-2/neu positivity rate of all the invasive breast cancers.  
Cases of ductal carcinoma in situ (DCIS) were eliminated from this calculation, as Her-2/neu 
testing is not currently performed on specimens of DCIS.  Out of the forty-two cases, there were 
six cases that had a diagnosis of ductal carcinoma in situ only.   Out of the thirty-six patients who 
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had an invasive breast cancer, seven tested positive for Her-2/neu amplification, or 19%, which 
is within the range of anticipated Her-2/neu positivity of 15 – 20%.  (Wolff, et al., 2013).  
The data analysis results of the indicators with a 90% benchmark are depicted in a graph 
in Appendix H, and the Her-2/neu positivity rates are depicted in Table 3, also in Appendix H. 
Evaluation 
The Breast Program Leadership Committee met on April 20, 2016 at which time, the 
results from the data collection were analyzed.  There was evidence that the interventions in the 
First and Second PDSA Cycles were effective in improving the performance in five out of the six 
indicators.  The quality indicators that met the benchmark of 90% or above included: 
Documentation of the time the specimen was removed from the body.  Documentation of 
the time the specimen was initially placed in formalin.  Documentation of the cold ischemic 
time, (the interval time in minutes between the removal from the blood supply and placement in 
formalin), and the percentage of cases in which the cold ischemic time was under 60 minutes.  
The Her-2/neu positivity rate was also calculated and compared to national averages.  The 
national average is currently 15 – 20% (Wolff et al., 2013), and our results were 19%, which is 
consistent with the national average.  The Breast Program Leadership Committee discussed 
actions to maintain the improvements made in these five indicators, which will be discussed 
more fully in the Plan for Sustainability.   
There was one remaining indicator that had not met the 90% Benchmark.  The indicator 
that did not met the 90% benchmark was the total time the specimen remained in formalin.  
ASCO/CAP Guidelines recommend that specimens remain in formalin a minimum of six hours, 
and should not exceed seventy-two hours (College of American Pathologists, 2013).  The Breast 
Program Leadership Committee reviewed the data collected on this indicator and determined that 
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since 100% of the specimens remained in formalin longer than six hours, under fixation of breast 
cancer specimens was not an issue.  However, twenty-two out of forty-two specimens remained 
in formalin longer than seventy-two hours, which accounted for 52% of specimens.  The range of 
hours that specimens spent in formalin was also reviewed.  The range was twenty-nine to one 
hundred and forty-four hours, and the average was eighty-two hours.  During the data analysis, a 
pattern was identified regarding this indicator.  The day of the week in which the specimen was 
initially removed from the body was recorded for all specimens.  When the twenty-two 
specimens that had spent over seventy-two hours in formalin were separated out and the days of 
the week on which the surgery was performed was looked at, it was found that twelve of the 
twenty-two cases in which the specimen spent over seventy-two hours in formalin were 
performed on Thursdays, accounting for 55%, and an additional five cases in which the specimen 
spent over seventy-two hours in formalin were performed on Fridays, or 23%.  Since a total of 
78% of the specimens that spent excessive time in formalin were from surgeries performed on a 
Thursday or Friday, we determined that surgeries that occur at the end of the week are at higher 
risk for over-exposure to formalin due to the fact that no pathology services are available on 
weekends.  Work on this last remaining indicator will be continued and further planning will 
occur at the next Breast Program Leadership Committee Meeting in June, 2016. 
Conclusion 
The Breast Cancer Specimen Collection & Handling quality improvement project has so 
far required three PDSA cycles to reach a point where five of the six indicators have successfully 
met their benchmarks.  Each PDSA cycle included a planning phase, a data collection phase that 
consisted of a retrospective chart audit, data analysis, an intervention, and additional planning 
before moving on to the next PDSA Cycle.  Five of the six indicators will move on to the plan 
BREAST CANCER SPECIMEN COLLECTION 47 
for sustainability, which will be discussed in depth in the next section.  The one remaining 
indicator that did not meet benchmark will continued to be investigated as discussed previously 
in the preceding section with the goal to initiate a plan for improvement by December 31, 2016. 
Plan for Sustainability 
Sustainability requires support from leadership but must also engage all stakeholders and 
employees for long term success.  Regular feedback regarding the status of improvement projects 
is critical to sustaining quality improvement over time.  In order to achieve this, there must be 
some form of tracking system, monitoring and reporting process and/or the improvement must be 
incorporated into daily operations.  (Association of State and Territorial Health Officials, n.d.) 
With regards to the Breast Cancer Specimen Collection and Handling Project, one indicator or 
metric has not met the 90% benchmark and will require additional planning for improvement.  
The metrics or indicators that successfully met their benchmarks and require a plan for 
sustainability include:   
Documentation of the time the specimen was removed from the blood supply. (The benchmark 
was 90% or above and the results of the third PDSA cycle was 95%) 
Documentation of the time the specimen was initially placed in formalin. (The benchmark was 
90% or above and the results of the third PDSA cycle was 90%) 
Documentation of the cold ischemic time. (The benchmark was 90% or above and the results of 
the third PDSA cycle was 90%)                         
The cold ischemic (total time from excision to placement in formalin) is 60 minutes or under. 
(The benchmark was 90% or above and the results of the third PDSA cycle was 100%) 
The Her-2 positivity rate within a range of 15 to 20%, by IHC or FISH testing. The benchmark 
was between 15 to 20%, which is consistent with the national rate of Her-2 positivity, and the 
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results for the 2nd PDSA Cycle was 15%, and the results for the 3rd PDSA Cycle was 19%, both 
within the expected range.  (Wolff, et al., 2013)  
After data analysis by the Breast Program Leadership Committee, the following 
recommendations were made for sustainability. 
Revision of all four different policies and procedures to comply with national guidelines, 
preferably one policy and procedure that is acceptable to all surgical sites.   
Identify at least one nursing leader at each of the four surgical sites to keep a pulse on 
nursing turnover, education needs and mentor new employees on proper breast cancer specimen 
collection and handling.  These nurse leaders would also report a need for education should there 
be a large turnover in nursing staff or any other identified reason for nursing education.   
Request the pathologist department set up a system to monitor compliance with 
documentation of the time the specimen is removed from the blood supply, documentation of the 
time it is placed in formalin, documentation of the cold ischemic time, compliance with the cold 
ischemic time that is 60 minutes or less, and the Her-/neu positivity rate between 15 – 20%.   In 
addition, we would ask that the pathologist that is a member of the Breast Program Leadership 
Committee to report the results of monitoring these indicators to the committee every other 
month at each of the meetings.   
Investigate whether a hard stop in the EPIC electronic health record system could be 
introduced that would not allow a nurse to move forward in a patient’s post-surgical chart 
without entering the time the specimen was removed from the body, the time it was placed in 
formalin and the cold ischemic time. 
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Review of the form that accompanies the specimen to the pathology department, 
determine whether the documentation of the times should be entered directly into the EPIC 
system, and whether the form is essential or whether it can be eliminated.   If the form is 
necessary, consider standardizing it across all four surgical sites.   
For the indicators that just met the benchmark of 90%, develop a plan to monitor 
compliance with additional chart audits until sustainability has been confirmed by meeting or 
exceeding the benchmarks consistently.  The number of chart audits are to be determined by the 
team and the results of subsequent chart audits.   
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Cause and Effect:  Fishbone Diagram 
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Appendix B 
 
 
Process Map Flowchart 
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Appendix C 
 
SWOT Analysis 
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Appendix D 
 
Stakeholder Analysis 
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Appendix E 
 
Failure Modes and Effects Analysis (FMEA) 
 
Link to:  Failure Modes and Effects Analysis Tool: Breast Cancer Specimen Collection & 
Handling Study.    
http://app.ihi.org/Workspace/tools/fmea/ProcessDetailDataReport.aspx?ToolId=19543&Scenario
Id=21483&Type=1 
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Appendix F 
 
Projected Cost Analysis & Cost Benefits Analysis 
 
 
 
 
 
 
 
 
 
Table 1.
John Muir Health - Breast Cancer Specimen Collection & Handling CQI Study - Anticipated Costs
Description Unit Cost Multiplier
PDSA Cycle 1 
2014
PDSA Cycle 2 
2015
PDSA Cycle 3 
2016 Total
Variable Costs
Labor Costs per Core Team 
Meeting 525.00 6 per cycle 3,150.00 3,150.00 3,150.00 9,450.00
Labor Costs per Multi-
disciplinary Team Meeting 1650.00 2 per cycle 3,300.00 3,300.00 3,300.00 9,900.00
Paid Time Mandatory 
Nursing In-services (Avg) 65.00 86 5,590.00 0.00 0.00 5,590.00
Paid Nurse Time - Chart 
Audits & Coordination 75.00 92 2,100.00 2,550.00 2,250.00 6,900.00
Catering/Refreshments 550.00 0.00 0.00 550.00
Second Intervention 
Physician & Team Webinar Sponsored 0.00 0.00 0.00 0.00
Office Supplies 75.00 150.00 75.00 300.00
Software/Applications 50.00 0.00 150.00 200.00
Total Variable Costs 14,815.00 9,150.00 8,925.00 32,890.00
Description Unit Cost Multiplier
Anticipated 
Savings - 2016 Total
Anticipated Cost Savings Resulting from Project
IHC Testing for Estrogen 
Receptors 167.00 400 66,800.00 66,800.00
IHC Testing for Progesterone 
Receptors 168.00 400 67,200.00 67,200.00
IHC Testing for HER-2/neu 
Receptor Amplification 167.00 400 66,800.00 66,800.00
FISH Testing for HER-2/neu 
Receptor Amplification 375.00 100 37,750.00 37,750.00
Total Anticipated Savings 238,550.00
Cost Benefit Analysis:  Savings - Costs = Anticipated Cost Benefit  238,550.00 - 32,890.00 =                        205,660.00
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Appendix G 
Table 2
Breast Cancer Specimen Collection & Handling 
Tasks, Dates & Responsible Person/Team
Task Name Start Date End Date 
Responsible 
Person/Team
Duration Percentage
Section 1 - Initial Identification of Problem 01/06/14 01/29/14 18d 100%
Sub-task 1 - Complaint from Surgeon Received 01/06/14 01/06/14 Medical 
Director
1d 100%
Subtask 2 - Initial Literature Search 01/07/14 01/14/14 Nurse 
Navigator
6d 100%
Sub-task 2 - CEBONS Presentation - Referenced 
National Guidelines & Issues with False 
Positives/False Negatives
01/22/14 01/22/14 Nurse 
Navigator
1d 100%
Sub-task 3 - Incident in 1 of 4 Surgery Sites: 
Specimen not placed in Formalin.  Left in surgery 
from Friday - Monday
01/27/14 01/29/14 Core Team 3d 100%
Section 2 - Verification of Problem with Specimen 
Collection & Handling
01/27/14 02/19/14 18d 100%
Sub-task 1 - Interviews with Breast Surgeons & 
Lead Pathologist
01/27/14 01/31/14 Medical 
Director
5d 100%
Sub-task 2 - Interviews with Surgical Nurses 02/03/14 02/07/14 Nurse 
Navigator
5d 100%
Sub-task 3 - Initial Chart Audit - 10 Charts of 
Breast CA patients
02/10/14 02/19/14 Nurse 
Navigator
8d 100%
Section 3 - First PDSA Cycle 03/03/14 12/22/14 211d 100%
Sub-task 1 - Multidisciplinary Team Formation 03/03/14 03/19/14 Core Team 13d 100%
Sub-task 2 - Multidisciplinary Team Meeting 03/19/14 03/19/14 Multi 
disciplinary 
Team
1d 100%
Sub-task 3 - Multidisciplinary Review & Planning 03/19/14 03/19/14 Multi disciplinary Team1d 100%
Sub-task 4 - Intervention:  Mandatory Education for 
Surgical Nurses Planning
03/31/14 07/07/14 Nurse 
Navigator
71d 100%
Sub-task 5 - Mandatory In-services for Surgical 
Nurses x 5
07/28/14 07/31/14 Genentech 
AOCN RN
4d 100%
Sub-Task 6 - Re-evaluation Plan for 2nd PDSA 
Cycle
08/04/14 12/22/14 Multi 
disciplinary 
Team
101d 100%
Section 4 - Second PDSA Cycle 01/05/15 11/16/15 226d 100%
Sub-Task 1 - Collected Lists of Patient for Chart 
Audit
01/05/15 01/19/15 Nurse 
Navigator
11d 100%
Sub-task 2 - Revision of Study, Additional Criteria 01/29/15 01/29/15 Core Team 1d 100%
Sub-task 3 - Retrospective Chart Audit & Data 
Collection
02/09/15 04/14/15 Nurse 
Navigator
47d 100%
Sub-task 4 - Initial Data Analysis & Identification of 
Trends
04/14/15 04/16/15 Nurse 
Navigator
3d 100%
Sub-task 5 - Comprehensive Data Analysis by 
Multidisciplinary Team
04/16/15 04/24/15 Multi 
disciplinary 
Team
7d 100%
Sub-task 6 - Intervention & 3rd PDSA Cycle Planning 05/20/15 07/29/15 Core Team 51d 100%
Sub-task 7 - Intervention:  Physician & Team Webinar 
& Discussion/Expert Pathologist David G. Hicks, M.D.
09/29/15 09/29/15 Nurse 
Navigator
1d 100%
Sub-task 8 - Re-evaluation & Plan for 3rd PDSA 
Cycle
11/16/15 11/16/15 Core Team 1d 100%
Section 5 - Third PDSA Cycle 01/18/16 04/20/16 68d
Sub-task 1 - Collected Lists of Patient for Chart Audit 01/18/16 01/20/16 Nurse 
Navigator
3d 100%
Sub-task 2 - Retrospective Chart Audit & Data 
Collection
02/01/16 03/15/16 Nurse 
Navigator
32d 100%
Sub-task 4 - Comprehensive Data Analysis by 
Multidisciplinary Team
04/20/16 04/20/16 Multi 
disciplinary 
Team
1d 0%
Section 6 - Study Completion & Plan for Follow-
up (If all criteria =/> 90%)
04/20/16 05/31/16 30d
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Appendix H  
Data Analysis Results 
 
 
 
Table 3   
Percentage of invasive carcinoma specimens that are Her-2/neu Amplified 
2014 2015 2016 
1st PDSA Cycle  2nd PDSA Cycle  3rd PDSA Cycle 
n/a 
5/33                 
15% 
7/36                 
19% 
Benchmark:  Rate of Her-2 Positivity 15 - 20% (Wolff, et al., 2013) 
 
